ArticleAnnals of internal medicine1991
Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.
Article in Annals of internal medicine, 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 7 registered trials, which are not on this map. Cited by 1,082 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension
Open the trial in the graphEndothelial Cell Dysfunction in Pulmonary Arterial Hypertension: Biomarkers, Mechanisms of Disease and Novel Therapeutic Targets
National, Prospective, Multicenter,Observational Registry Study on Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension in China
A Natural History Study of Novel Biomarkers in Pulmonary Arterial Hypertension
Pulmonary Hypertension in Preterm Children Born at Gestational Age <30 Weeks: Prevalence, Risk Factors and Outcome
A Single-Center, Blinded, Randomized Control Trial Evaluating Different Approaches to Evaluation of Right Ventricular Size and Function Using the Upper Valley Right Ventricle Algorithm and Novel Imaging Modalities
Use of Non-invasive Measurement of Cardiac Output and Stroke Volume to Assess Risk and Response to Treatment in Patients With PAH or CTEPH
Who cites it
1,082 citing papers in PubMed, 3 syntheses or guidelines pooled it, 3,486 citations in OpenAlex.
- Impact of BMPR2 mutation on the severity of pulmonary arterial hypertension: a systematic review and meta-analysis.Respiratory research · 2025Pooled it
- Survival, morbidity, and quality of life in pulmonary arterial hypertension patients: a systematic review of outcomes reported by population-based observational studies.Respiratory research · 2024Pooled it
- Risk stratification in adult and pediatric pulmonary arterial hypertension: A systematic review.Frontiers in cardiovascular medicine · 2022Pooled it
- Bioequivalence and the food effect of macitentan/tadalafil 10/20 fixed-dose combination tablets versus the use of single-component tablets in healthy subjects.Pharmacology research & perspectives · 2024Trial
- Ralinepag Phase II Open-Label Extension Study in Patients with Pulmonary Arterial Hypertension.Advances in therapy · 2024Trial
- The ALPHA phase 1 study: pulmonary ArteriaL hypertension treated with CardiosPHere-Derived allogeneic stem cells.EBioMedicine · 2024Trial
- Article
- Development of a population pharmacokinetic model using combined paediatric and adult data for four pulmonary arterial hypertension drugs.British journal of clinical pharmacology · 2026Article
- Beyond the Heart-Lung Axis: A Review of the Crosstalk Between the Hemodynamic, Neurohormonal, and Immune Systems in Pulmonary Hypertension.Comprehensive physiology · 2026Review
- Alterations in the fecal virome and bacteriome-virome interplay in IPAH.Respiratory research · 2026Article
- The Relationship Between Vortical Flow and Pressure Gradient Reversal in Pulmonary Hypertension-A 4D Analysis of Cardiovascular Magnetic Resonance Flow Imaging.Pulmonary circulation · 2026Article
- Navigating the Complexities of Pulmonary Hypertension Care: Unique Challenges in PAH Management.Pulmonary circulation · 2026Review
- Prognostic Value of Right Atrial Adverse Remodeling in Patients With Pulmonary Arterial Hypertension.Pulmonary circulation · 2026Article
- Article
- Sodium Selenite Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension by Upregulating GPX3 and Ameliorating Vascular Remodeling.Physiological research · 2026Article
- Treatment of Pulmonary Arterial Hypertension in Lithuania: Current Situation and Analysis of Survival of Patients Treated with Different Treatment Regimens.Journal of clinical medicine · 2026Article
- Clinical, serological and haemodynamic factors associated with poor outcomes in systemic lupus erythematosus-associated pulmonary arterial hypertension: a multicentre retrospective study from Korea.Rheumatology (Oxford, England) · 2026Article
- Iron Deficiency in Pulmonary Hypertension-Prevalence, Impact on Prognosis and Disease Burden in Pulmonary Arterial Hypertension and Pulmonary Hypertension Related to Hypoxia: A Review.International journal of molecular sciences · 2026Review
- Feasibility and safety of right heart catheterization via median cubital vein in patients with pulmonary hypertension.BMC cardiovascular disorders · 2026Article
- Value of right heart haemodynamics for risk stratification of patients with pulmonary arterial hypertension at follow-up.ESC heart failure · 2026Article
1,022 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 12 institutions in 1 country.
Funding
Abstract
objectiveTo characterize mortality in persons diagnosed with primary pulmonary hypertension and to investigate factors associated with survival.
designRegistry with prospective follow-up.
settingThirty-two clinical centers in the United States participating in the Patient Registry for the Characterization of Primary Pulmonary Hypertension supported by the National Heart, Lung, and Blood Institute. PATIENTS: Patients (194) diagnosed at clinical centers between 1 July 1981 and 31 December 1985 and followed through 8 August 1988. MEASUREMENTS: At diagnosis, measurements of hemodynamic variables, pulmonary function, and gas exchange variables were taken in addition to information on demographic variables, medical history, and life-style. Patients were followed for survival at 6-month intervals. MAIN
resultsThe estimated median survival of these patients was 2.8 years (95% Cl, 1.9 to 3.7 years). Estimated single-year survival rates were as follows: at 1 year, 68% (Cl, 61% to 75%); at 3 years, 48% (Cl, 41% to 55%); and at 5 years, 34% (Cl, 24% to 44%). Variables associated with poor survival included a New York Heart Association (NYHA) functional class of III or IV, presence of Raynaud phenomenon, elevated mean right atrial pressure, elevated mean pulmonary artery pressure, decreased cardiac index, and decreased diffusing capacity for carbon monoxide (DLCO). Drug therapy at entry or discharge was not associated with survival duration.
conclusionsMortality was most closely associated with right ventricular hemodynamic function and can be characterized by means of an equation using three variables: mean pulmonary artery pressure, mean right atrial pressure, and cardiac index. Such an equation, once validated prospectively, could be used as an adjunct in planning treatment strategies and allocating medical resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.